P
Precision BioSciences, Inc. (DTIL)
NCM – Real Time Price. Currency in USD
7.29
+0.54 (8.00%)
At close: Jun 26, 2026, 4:00 PM EDT
7.21
-0.08 (-1.10%)
After-hours: Jun 26, 2026, 6:53 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
7.29
+0.54 (8.00%)
At close: Jun 26, 2026, 4:00 PM EDT
7.21
-0.08 (-1.10%)
After-hours: Jun 26, 2026, 6:53 PM EDT
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Name | Position |
|---|---|
| Dr. Cassie Gorsuch Ph.D. | Chief Scientific Officer |
| Dr. Jefferson J. Smith Ph.D. | Co-Founder & Chief Research Officer |
| Mr. Dario Scimeca J.D. | General Counsel & Secretary |
| Mr. John Alexander Kelly R.Ph. | CFO & Principal Accounting Officer |
| Mr. Michael Amoroso | President, CEO & Director |
| Mr. Naresh Tanna | Chief of Staff to CEO & Head of Investor Relations |
| Mr. Neil Leatherbury M.S. | Senior VP and Head of Chemistry, Manufacturing & Controls |
| Ms. Cindy Atwell | Chief Development & Business Officer |
| Ms. Juli Blanche | Chief People Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-16 | 8-K | dtil-20260610.htm |
| 2026-05-27 | 8-K | dtil-20260527.htm |
| 2026-05-26 | 8-K | dtil-20260521.htm |
| 2026-05-05 | 8-K | dtil-20260505.htm |
| 2026-04-08 | DEFA14A | ny20064330x3_defa14a.htm |
| 2026-04-08 | DEF 14A | ny20064330x2_def14a.htm |
| 2026-04-08 | ARS | ny20064330x4_ars.pdf |
| 2026-03-27 | PRE 14A | ny20064330x1_pre14a.htm |
| 2026-03-17 | 8-K | dtil-20260317.htm |
| 2026-03-12 | 8-K | dtil-20260312.htm |